Literature DB >> 26088592

Video-assisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy.

Lykke Østergaard Laursen1, René Horsleben Petersen2, Henrik Jessen Hansen2, Tina Kold Jensen3, Jesper Ravn2, Lars Konge4.   

Abstract

OBJECTIVES: Lung cancer is the most common cause of cancer-related deaths worldwide. Survival is highly dependent on surgery. Video-assisted thoracoscopic surgery (VATS) is increasingly chosen over open thoracotomy (OT) because of the possible benefits of the minimally invasive approach. Consequently, our aim was to compare the 30-day morbidity and mortality for lung cancer patients operated by VATS lobectomy or lobectomy by OT.
METHOD: Data were obtained from prospective national and regional databases, including patients who underwent lobectomy for lung cancer in the eastern part of Denmark from 1 January 2005 to 31 December 2011. All patients operated before 2009 were re-staged according to the latest International Association for the Study of Lung Cancer lung cancer classification. Patient characteristics, comorbidities, pathology and operative data were assessed using an independent samples t-test, Pearson's χ(2), Fisher's exact test and Mann-Whitney test. Morbidity was assessed using multinomial logistic regression adjusted for gender, age, cancer stage, forced expiratory volume in 1 s (FEV1), year of surgery and Charlson comorbidity score.
RESULTS: In total, 1379 patients underwent lobectomy, 785 patients via VATS and 594 patients via thoracotomy. The two groups were similar in gender and FEV1. The patients operated by VATS were older (P < 0.001), and had a lower Charlson comorbidity score (P = 0.034), higher frequency of adenocarcinomas (P < 0.001) and lower cancer stage (P < 0.001). Among the VATS patients, 285 (36.3%) and among the thoracotomy patients, 288 (48.5%) had minor complications (P < 0.001); and 157 (20.0%) VATS patients and 212 (35.7%) thoracotomy patients had major complications (P < 0.001). The 30-day mortality rate was 1% in the VATS group and 1.5% in the thoracotomy group (P = 0.47). Multinomial logistic regression analysis showed that the prevalence of both minor [odds ratio (OR) = 1.51; 95% confidence interval (Cl) = 1.18-1.96] and major complications (OR = 1.91, 95% Cl = 1.44-2.53) was significantly higher for patients who underwent lobectomy via thoracotomy compared with VATS.
CONCLUSION: Patients undergoing lobectomy via VATS were less likely to have at least one minor complication within the first 30 postoperative days and less likely to have at least one major complication, compared with patients operated by thoracotomy. These findings remained after adjusting for gender, age, FEV1, cancer stage, year of surgery and Charlson comorbidity score.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Complications; Lung cancer; Morbidity; Thoracotomy; Video-assisted thoracoscopic surgery

Mesh:

Year:  2015        PMID: 26088592     DOI: 10.1093/ejcts/ezv205

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  50 in total

1.  Is it safe to perform completion lobectomy after diagnostic wedge resection using video-assisted thoracoscopic surgery?

Authors:  Bo Laksáfoss Holbek; René Horsleben Petersen; Henrik Jessen Hansen
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-02-25

2.  Does the number of incisions in video-assisted thoracoscopic surgery matter?

Authors:  Henrik Jessen Hansen; Gonzalo Varela; René Horsleben Petersen; William S Walker
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

3.  Does videomediastinoscopy with frozen sections improve mediastinal staging during video-assisted thoracic surgery pulmonary resections?

Authors:  Alessandro Gonfiotti; Stefano Bongiolatti; Domenico Viggiano; Sara Borgianni; Roberto Borrelli; Giorgia Tancredi; Massimo O Jaus; Leonardo Politi; Camilla E Comin; Luca Voltolini
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 4.  Design and implementation of an enhanced recovery program in thoracic surgery.

Authors:  Marc Giménez-Milà; Andrew A Klein; Guillermo Martinez
Journal:  J Thorac Dis       Date:  2016-02       Impact factor: 2.895

5.  Treatment of anaemia in the "ERAS" era: how far can we go?

Authors:  Luigi Rolli; Leonardo Duranti; Giovanni Leuzzi
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

6.  Outcomes after Video-assisted Thoracoscopic Lobectomy versus Open Lobectomy for Early-Stage Lung Cancer in Older Adults.

Authors:  Nicole Ezer; Minal Kale; Keith Sigel; Sameer Lakha; Grace Mhango; Emily Goodman; Daniel Nicastri; Scott Swanson; Alfred Neugut; Juan P Wisnivesky
Journal:  Ann Am Thorac Soc       Date:  2018-01

7.  Understanding patients' values and preferences regarding early stage lung cancer treatment decision making.

Authors:  Donald R Sullivan; Karen B Eden; Nathan F Dieckmann; Sara E Golden; Kelly C Vranas; Shannon M Nugent; Christopher G Slatore
Journal:  Lung Cancer       Date:  2019-03-09       Impact factor: 5.705

Review 8.  Enhanced recovery after surgery and video-assisted thoracic surgery lobectomy: the Italian VATS Group surgical protocol.

Authors:  Alessandro Gonfiotti; Domenico Viggiano; Luca Voltolini; Alessandro Bertani; Luca Bertolaccini; Roberto Crisci; Andrea Droghetti
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

9.  A novel assessment tool for evaluating competence in video-assisted thoracoscopic surgery lobectomy.

Authors:  Katrine Jensen; René Horsleben Petersen; Henrik Jessen Hansen; William Walker; Jesper Holst Pedersen; Lars Konge
Journal:  Surg Endosc       Date:  2018-03-30       Impact factor: 4.584

10.  Risk factors and impact of conversion from VATS to open lobectomy: analysis from a national database.

Authors:  Stefano Bongiolatti; Alessandro Gonfiotti; Domenico Viggiano; Sara Borgianni; Leonardo Politi; Roberto Crisci; Carlo Curcio; Luca Voltolini
Journal:  Surg Endosc       Date:  2019-01-31       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.